SCHEMBL8259595

SCHEMBL8259595

CCc1c(Cl)c(=O)n(-c2ccc(F)cc2)n1C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FPR2 P25090 3/20 0.41
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
RAB9A P51151 2/20 0.37
NPSR1 Q6W5P4 2/20 0.37
MITF O75030 1/20 0.37
PKM P14618 1/20 0.37
HTT P42858 1/20 0.37
KCNH2 Q12809 1/20 0.37
BRD9 Q9H8M2 1/20 0.36
BRD4 O60885 1/20 0.35
KAT2B Q92831 1/20 0.35
BPTF Q12830 1/20 0.35
GSK3A P49840 1/20 0.34
GSK3B P49841 1/20 0.34
MAPT P10636 1/20 0.34
THRB P10828 1/20 0.34
ALDH1A1 P00352 2/20 0.34
NPBWR1 P48145 1/20 0.34
NPC1 O15118 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4325141 0.86 MEN1 (0.38) FPR2MEN1KMT2ARAB9ANPSR1
SCHEMBL4318567 0.84 FPR2 (0.54) FPR2MEN1KMT2ANPSR1THRB
SCHEMBL5264271 0.84 MEN1 (0.36) FPR2MEN1KMT2ARAB9ANPSR1
SCHEMBL4318702 0.79 KMT2A (0.51) FPR2MEN1KMT2ARAB9ATHRB
SCHEMBL1259421 0.78 FPR2 (0.42) FPR2MEN1KMT2AALDH1A1LMNA
SCHEMBL8258475 0.75 ALDH1A1 (0.47) FPR2MEN1KMT2ARAB9ANPSR1
SCHEMBL4332386 0.75 SMO (0.54) HTTMAPTALDH1A1LMNASMN1; SMN2
SCHEMBL4327601 0.74 SMN1; SMN2 (0.47) RAB9ANPSR1ALDH1A1NPC1LMNA
SCHEMBL1258186 0.74 KMT2A (0.46) MEN1KMT2ARAB9AMAPTALDH1A1
SCHEMBL4334363 0.73 FPR2 (0.41) FPR2MEN1KMT2ARAB9ANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2006071730-A1 PYRAZOLONE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR AGONISTS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS ASTRAZENECA AB (SE) 2006-07-06 WO disclosed